Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06364085
Other study ID # DBS2024
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date June 2026

Study information

Verified date April 2024
Source Nova Scotia Health Authority
Contact Lutz Weise, MD, PhD
Phone 902-472-6850
Email lutz.weise@nshealth.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.


Description:

Aim 1: To objectively monitor epilepsy burden with the provided sensing capabilities of the DBS leads by quantifying the association between neuronal activity and seizure frequency Aim 2: To use the neuronal activity to inform programming of DBS for patients with epilepsy, and assess the impact on patient and caregiver quality of life and hospital costs. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures that affects millions of individuals worldwide and poses a significant burden on their quality of life. Despite considerable advancements in treatment strategies, approximately one-third of patients are considered to have drug-resistant epilepsy. Patients with drug-resistant epilepsy frequently visit the emergency room, are hospitalized regularly, and have many seizure-related injuries. Deep brain stimulation (DBS) offers a unique treatment option by delivering precise electrical pulses with surgically implanted electrodes to the specific brain regions responsible for seizures, disrupting the seizure pathways. Long-term favorable findings showing significant seizure reduction at five-year post-implantation for patients who otherwise have no treatment options have convinced many centers to incorporate DBS into their healthcare practise. For assessing the treatment response in epilepsy, healthcare providers are dependent on patient-reported seizure diaries. Recent research in DBS has focused on the biological implications of neuronal recordings through the implanted electrodes. These signals offer objective insight into brain activity, specifically epileptic burden, and offers potentially predictive capabilities. Current research focuses on whether the sensing capabilities of DBS can provide reliable seizure burden detection, and whether this can be achieved with less demand on the patient. In this prospective observational cohort study, the researchers aim to improve the impact of DBS treatment on the seizure burden and quality of life of patients diagnosed with drug-resistant epilepsy in Atlantic Canada. This will be done by investigating the neural activity underlying epileptic events as a representation of epileptic burden, affording the opportunity to tailor DBS interventions with more precision and efficiency.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients qualifying for deep brain stimulation on the basis of drug-resistant epilepsy - Informed consent Exclusion Criteria: - Lack of consent - Electrical or other devices that preclude the performance of an MRI for pre-operative imaging

Study Design


Intervention

Device:
Neuromodulation programming
Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming. Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up.

Locations

Country Name City State
Canada Queen Elizabeth Health Science Centre Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seizure reduction The number of seizures experienced by patients will be assessed by the number of seizures recorded by patients and their caregivers in seizure diaries and described as absolute seizure reduction. Change from baseline versus Month 12
Secondary Change in disease score on Patient Weighted Quality Of Life In Epilepsy Assessment of therapeutic effects using Patient Weighted Quality Of Life In Epilepsy, a 10-question survey completed by patients to assess quality of life, where a higher score is associated with a more positive quality of life. Twelve months
Secondary Change in depression score on Neurological Disorders Depression Inventory in Epilepsy Assessment of therapeutic effects using Neurological Disorders Depression Inventory in Epilepsy, a 6-question survey to assess depression. A higher score is associated with more severe depression. Twelve months
Secondary Change in anxiety score on Anxiety General Anxiety Disorder-7 Assessment of therapeutic effects using Anxiety General Anxiety Disorder-7, a 7-question survey to assess anxiety. A higher score is associated with more severe anxiety, and a lower score is associated with minimal anxiety. Twelve months
See also
  Status Clinical Trial Phase
Completed NCT03183076 - Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy N/A
Completed NCT04181229 - Deep Brain Stimulation Post Failed Vagal Nerve Stimulation N/A
Recruiting NCT04673071 - Effectiveness and Safety of Thread Embedding Acupuncture for Drug Resistant Epilepsy N/A
Recruiting NCT04166305 - Drug Resistant Epilepsy: Clinical and Genetic Study
Not yet recruiting NCT06436547 - Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB) N/A
Completed NCT03860298 - Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy N/A
Recruiting NCT06248333 - Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy N/A